Supported by

Tricuspid / Pulmonary valve

Latest tricuspid content in interventional cardiology - research, practice, and education

Endovascular treatments for complications of the tricuspid or pulmonary valve, such as the treatment for tricuspid regurgitation (TR), are at an early stage of clinical development with many novel devices being introduced each year. This topic explores the different parameters of this emerging field with information on the latest research, emerging tools, devices and techniques, vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography as well as understanding bleeding risks or patient selection. Find out more…

Filtered By
Tricuspid / Pulmonary valve

523 results

What are the key considerations when managing combined mitral and tricuspid regurgitation?

17 Feb 2026 – From PCR London Valves 2025

Fabien Praz and Neil Fam talk about the management of patients with combined mitral and tricuspid regurgitation, who are often elderly with heart failure and multiple comorbidities. Careful assessment—including echocardiography, hemodynamics, and sometimes CT—is crucial to identify the dominant lesion. Surgery is preferred if feasible, but...

What are the key considerations when managing combined mitral and tricuspid regurgitation?

How do we meet the needs of women with heart valve disease?

27 Mar 2026 – From PCR London Valves 2025

In this interview, Ellen Ross and Marta Sitges discuss a recent initiative from Global Heart Hub - a patient association - which examined the realities faced by women living with heart valve disease. They outline the gaps identified, the call to action that followed, and how...

How do we meet the needs of women with heart valve disease?

How are the new ESC/EACTS valvular guidelines going to impact my tricuspid programme?

17 Nov 2025 – From PCR London Valves 2025

While the PCR London Valves 2025 Course is underway, Francesco Maisano and Fabien Praz discuss how the latest ESC/EACTS valvular guidelines affect clinical practice. What’s changing in surgery? How do repair and replacement strategies differ under the new recommendations, and what’s the impact on transcatheter interventions?...

How are the 2025 ESC/EACTS valvular guidelines going to impact my tricuspid programme?

Tricuspid valve: PCR London Valves 2025 highlights

18 Nov 2025 – From PCR London Valves 2025

At PCR London Valves 2025, Course Directors Francesco Maisano and Nicolo Piazza highlight with Chris Allen the rapid evolution of tricuspid interventions. They emphasise advances in imaging and simulation, with dedicated labs offering practical multimodality training and hands-on experience. LIVE cases showcased both repair and replacement...

Tricuspid valve: PCR London Valves 2025 highlights

From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system

16 Nov 2025 – From PCR London Valves 2025

Rebecca Hahn, Varius Dannenberg and Matti Adam discuss the updated ESC/EACTS guidelines for tricuspid regurgitation, which upgrade transcatheter tricuspid interventions to a IIa recommendation. Evidence from the TRILUMINATE and TRISCEND II trials shows improved quality of life and reduced heart failure hospitalisations, especially in patients with...

From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system #PCRLV

Cracking the tricuspid code "the Bicaval revolution"

16 Nov 2025 – From PCR London Valves 2025

This session decodes the advancement of caval valve therapy with the TricValve system, offering novel solutions for tricuspid regurgitation and right heart failure. It incorporates insights from clinical trials, real-world cases, and guideline integration, detailing imaging techniques and strategies for complex patient management including rescue interventions.

Cracking the tricuspid code 'the Bicaval revolution'

From repair to replacement: a portfolio of options for your mitral and tricuspid regurgitation patients

16 Nov 2025 – From PCR London Valves 2025

This session explores a full spectrum of therapeutic options for mitral and tricuspid regurgitation, focusing on the PASCAL Precision system for targeted repair and the SAPIEN M3 transcatheter mitral valve replacement. Through beating heart simulators, case discussions, and clinical evidence, participants will understand the versatility and...

From repair to replacement: a portfolio of options for your mitral and tricuspid regurgitation patients

Cutting-edge research in transcatheter tricuspid valve therapies

16 Nov 2025 – From PCR London Valves 2025

This session highlights cutting-edge research on tricuspid valve interventions, including the impact of inflow gradients on outcomes, global registry data on bicaval valve therapy, patient selection algorithms, and prognostic score validations for severe tricuspid regurgitation.

Cutting-edge research in transcatheter tricuspid valve therapies

New tricuspid valve devices

16 Nov 2025 – From PCR London Valves 2025

Examine new tricuspid valve devices and innovative procedural approaches, featuring cases of challenging anatomy with pacemaker lead repositioning, use of LuX-valve plus in massive regurgitation, position optimization in transjugular TTVR, and early clinical experiences from feasibility studies.

Focus on the right ventricle: patient selection and clinical outcomes after tricuspid valve intervention

16 Nov 2025 – From PCR London Valves 2025

Focused on the often-overlooked right ventricle, this session elucidates methods for accurate assessment of right ventricular function prior to transcatheter tricuspid valve interventions. It explores the role of right heart catheterisation in patient selection and timing, and evaluates long-term remodeling patterns post-procedure, providing critical insights for...

Focus on the right ventricle: patient selection and clinical outcomes after tricuspid valve intervention